Skip to content

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›TENARIS SA (TNRSF)

TENARIS SA

TNRSF

Held by 1 specialist biotech fund

1 fund opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus CapitalNew

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalNEWMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ABBV1 fund ABCL1 fund ADPT1 fund AMD1 fund AEM1 fund AKTS1 fund ALGN1 fund ALKS1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

TNRSF: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge